Dermatomyositis, Adult Type
5 clinical trials · Condition
◉ Watch Dermatomyositis, Adult Type
| Record | Firm | Date |
|---|---|---|
| A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis (NCT06433999) | Priovant Therapeutics, Inc. | 2024-08-28 |
| Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis (NCT05986162) | Biotech Pharmaceutical Co., Ltd. | 2023-12-30 |
| Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis (NCT05375435) | The First Affiliated Hospital with Nanjing Medical University | 2022-01-01 |
| The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients (NCT04966884) | First Affiliated Hospital Xi'an Jiaotong University | 2020-04-02 |
| Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis (NCT03529955) | Tulane University | 2018-06-12 |
Track Dermatomyositis, Adult Type automatically
Every clearance here is in the API, with alerts when new ones post.